The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...

Reports Q4 revenue $ $3.71M , consensus $5.47M…Bicycle Therapeutics (BCYC) is currently conducting the Phase 2/3 Duravelo-2 registrational ...

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...

Medicenna Therapeutics Corp. shares T.MDNA are trading unchanged at $1.13.

Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothe ...

A GROUNDBREAKING cancer vaccine reversed the disease in nine patients, a study has shown. They remained disease free three ...

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.

Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further ...